what are the risks of glp 1 drugs America's Poison Centers GLP-1 Receptor Agonists | New
Description
Dual peptides for the treatment of obesity Tirzepatide, a novel dual GIP and GLP-1RA, offers significant insights into its mechanism of action, therapeutic benefits, and clinical applications for the management of T2D and obesity in general practice
10.1210/en.2012-1855 50
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: Systematic review and meta-analysis
doi:10.1038/labinvest.2015.35 110
Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Pilitsi E, et al
Novo Nordisks newest drug, CagriSema, led to greater weight loss than semaglutide, according to results presented Sunday at the conference
